ARBM 201
Alternative Names: ARBM-201; YS-01Latest Information Update: 28 Jun 2024
At a glance
- Originator Yonsei University Health System
- Developer ArborMed
- Class Anti-inflammatories; Small molecules
- Mechanism of Action SLC26A4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome
Most Recent Events
- 17 May 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Acute respiratory distress syndrome presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
- 11 Jul 2022 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Acute respiratory distress syndrome released by ArborMed, prior to July 2022
- 13 May 2022 Preclinical trials in Adult respiratory distress syndrome in South Korea (IV)